Annals Meeting Reports (7)
Published: October 2011
This volume presents three meeting reports. (1) Toward an interdisciplinary science of consumption; (2) Wild immunology: converging on the real world; and (3) Advancing drug discovery for schizophrenia.
Scientific perspectives on the drive to consume were presented in Ann Arbor, Michigan, at the conference entitled “The Interdisciplinary Science of Consumption: Mechanisms of Allocating Resources Across Disciplines.” The meeting, which took place May 12–15, 2010 and was sponsored by Rackham Graduate School and the Department of Psychology at the University of Michigan, included presentations on human, primate, and rodent models and spanned multiple domains of consumption, including reward seeking, delay discounting, food-sharing reciprocity, and the consumption and display of material possessions across the life span.
Centre for Immunity, Infection, and Evolution (CIIE) sponsored a one-day symposium entitled “Wild Immunology”. The CIIE is a new Wellcome Trust-funded initiative with the remit to connect evolutionary biology and ecology with research in immunology and infectious diseases in order to gain an interdisciplinary perspective on challenges to global health. The central question of the symposium was, “Why should we try to understand infection and immunity in wild systems?” Specifically, how does the immune response operate in the wild and how do multiple coinfections and commensalism affect immune responses and host health in these wild systems? The symposium brought together a broad program of speakers, ranging from laboratory immunologists to infectious disease ecologists, working on wild birds, feral animals, wild and laboratory rodents and on questions ranging from the dynamics of coinfection to how commensal bacteria affect the development of the immune system. The meeting on wild immunology, organized by Amy Pedersen, Simon Babayan, and Rick Maizels, was held at the University of Edinburgh, UK on 30th June, 2011.
Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, “Advancing Drug Discovery for Schizophrenia” was held March 9–11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.
Explore the Digital Issue
Members receive free unlimited access to Annals. Enjoy exploring topics, searching through the archive, uncovering insights and continuing to benefit from the World's Smartest Network.
Unlimited access to Digital Annals
Special pricing for Events and Print Issues
Exclusive Members-only content
Already a member? Login